Description
A potent, selective 5-HT2A receptor antagonist with Ki of 0.36nM, >80-fold selectivity for 5-HT2A over other serotonergic receptors; demonstrates a clozapine-like profile of potential antipsychotic activity with low extrapyramidal sid-effect liability, and has a superior CNS safety index. Sleep Disorder Phase 3 Discontinued